Lawrence Steinman

The molecular basis of EBV triggering multiple sclerosis 3:57
The molecular basis of EBV triggering multiple sclerosis
Lawrence Steinman • 11 Apr 2022
Important lines of research in progressive multiple sclerosis 2:54
Important lines of research in progressive multiple sclerosis
Lawrence Steinman • 11 Apr 2022
Relapse rate from the ULTIMATE studies of ublituximab for relapsing MS 1:52
Relapse rate from the ULTIMATE studies of ublituximab for relapsing MS
Lawrence Steinman • 11 Apr 2022
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS 3:26
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman • 15 Oct 2021
Ublituximab: pending approval for relapsing MS 1:41
Ublituximab: pending approval for relapsing MS
Lawrence Steinman • 15 Oct 2021
How does ublituximab compare to other anti-CD20 mAbs? 1:14
How does ublituximab compare to other anti-CD20 mAbs?
Lawrence Steinman • 15 Oct 2021
ULTIMATE I & II results: ublituximab versus teriflunomide in relapsing MS 3:27
ULTIMATE I & II results: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman • 11 Jun 2021
Novel agents are needed for the treatment of multiple sclerosis 3:08
Novel agents are needed for the treatment of multiple sclerosis
Lawrence Steinman • 11 Jun 2021
The content of VJNeurology is intended for healthcare professionals